You know the old saying: “If at first you don’t succeed, try, try again.”
That’s exactly what MannKind (NASDAQ: MNKD) is doing. The biotech’s CEO Matthew Pfeiffer talked about a new plan for the company in 2017 at the J. P. Morgan Healthcare Conference last week. What is this new plan — and will it work?
